Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma - Esmaeli, B; McLaughlin, P; Pro, B (Ann Oncol, 2009)